Target intelligence / Profile preview

Fungal polysaccharide antigens

Molecular classification
Polysaccharide, Carbohydrate, Pathogen-associated molecular pattern (PAMP)
01

Overview

Fungal polysaccharide antigens are essential carbohydrate polymers, such as (1,3)-beta-D-glucan, galactomannan, and mannan, that form the structural backbone of the fungal cell wall (Erwig & Gow, 2016, Nature Reviews Microbiology). These molecules are unique to fungi and are absent in human cells, making them highly specific targets for both diagnostic assays and therapeutic interventions. In the host, these antigens act as pathogen-associated molecular patterns (PAMPs) that trigger innate immune responses through receptors like Dectin-1 (Brown, 2006, Nature). Clinically, the detection of these antigens in serum or bronchoalveolar lavage fluid serves as a critical biomarker for the early diagnosis of life-threatening invasive fungal infections (Karageorgopoulos et al., 2011, Clinical Infectious Diseases). Therapeutic agents like echinocandins (e.g., caspofungin) work by inhibiting the synthesis of these polysaccharides, specifically targeting the (1,3)-beta-D-glucan synthase enzyme to cause cell wall instability and fungal death (StatPearls, 2023). Additionally, these antigens are the focus of research into monoclonal antibodies and vaccines aimed at enhancing the host's ability to clear fungal pathogens.

Other names
Fungal cell wall polysaccharidesBeta-glucansGalactomannansMannansChitinGlucuronoxylomannanPAMPs (Pathogen-Associated Molecular Patterns)
02

Mechanism of action

Inhibition of (1,3)-beta-D-glucan synthase, leading to depletion of cell wall polysaccharides and osmotic instability; direct binding by monoclonal antibodies for opsonization and clearance.

03

Biological functions

Cell wall structural integrityImmune recognitionVirulence factorOsmotic protection
04

Disease associations

Invasive fungal infectionCandidiasisAspergillosisCryptococcosisPneumocystis pneumonia
05

Safety considerations

False-positive diagnostic results due to cross-reactivity with medical materialsLimited efficacy against fungi lacking specific polysaccharides (e.g., Cryptococcus)Potential for resistance through cell wall remodeling and chitin upregulation
06

Interacting drugs

Caspofungin

5 more in the full profile.

07

Biomarkers

(1,3)-beta-D-glucan (BDG)Galactomannan (GM)Cryptococcal antigen (CrAg)Mannan antigen

Beyond the preview

Go deeper on Fungal polysaccharide antigens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fungal polysaccharide antigens.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call